EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 2 (Février 2025) Med Sci (Paris), 41 2 (2025) 154-159 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 2, Février 2025
Page(s) 154 - 159
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025011
Published online 03 March 2025
  1. Abate-Shen C. Molecular genetics of prostate cancer. Genes Dev 2000 ; 14 : 2410–34. [CrossRef] [PubMed] [Google Scholar]
  2. Sakr WA, Haas GP, Cassin BF, et al. The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients. J. Urol 1993 ; 150 : 379–85. [CrossRef] [PubMed] [Google Scholar]
  3. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005 ; 436 : 725–30. [CrossRef] [PubMed] [Google Scholar]
  4. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016 ; 40 : 244–52. [CrossRef] [PubMed] [Google Scholar]
  5. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers 2021 ; 7 : 9. [CrossRef] [PubMed] [Google Scholar]
  6. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010 ; 21 : 2135–44. [CrossRef] [PubMed] [Google Scholar]
  7. Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 2022 ; 3 : 100613. [CrossRef] [PubMed] [Google Scholar]
  8. Grelet É, Parisotto M, Metzger D. Comment limiter la progression des tumeurs prostatiques déficientes en PTEN ? Med Sci (Paris) 2018 ; 34 : 904–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Dariane C, Baures M, Anract J, et al. Progéniteurs luminaux prostatiques: de la régénération tissulaire à la résistance thérapeutique. Med Sci (Paris) 2023 ; 39 : 429–36. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Sackmann Sala L, Boutillon F, Menara G, et al. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours. J. Pathol 2017 ; 243 : 51–64. [CrossRef] [PubMed] [Google Scholar]
  11. Abu el Maaty MA, Terzic J, Keime C, et al. Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression. Sci Adv 2022 ; 8 : eabo2295. [CrossRef] [PubMed] [Google Scholar]
  12. Tuong ZK, Loudon KW, Berry B, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep 2021 ; 37 : 110132. [CrossRef] [PubMed] [Google Scholar]
  13. Linxweiler J, Hajili T, Körbel C, et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep 2020 ; 10 : 12575. [CrossRef] [PubMed] [Google Scholar]
  14. Bravi CA, Rosiello G, Fallara G, et al. Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. Minerva Urol Nephrol 2021 ; 73. [Google Scholar]
  15. Bancaro N, Calì B, Troiani M, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell 2023 ; 41 : 602–19.e11. [CrossRef] [PubMed] [Google Scholar]
  16. Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 2018 ; 559 : 363–9. [CrossRef] [PubMed] [Google Scholar]
  17. Guo C, Sharp A, Gurel B, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature 2023 ; 623 : 1053–61. [CrossRef] [PubMed] [Google Scholar]
  18. Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017 ; 543 : 728–32. [CrossRef] [PubMed] [Google Scholar]
  19. Murphy AB, Nyame Y, Martin IK, et al. Vitamin D Deficiency Predicts Prostate Biopsy Outcomes. Clin Cancer Res 2014 ; 20 : 2289–99. [CrossRef] [PubMed] [Google Scholar]
  20. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019 ; 380 : 33–44. [CrossRef] [PubMed] [Google Scholar]
  21. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014 ; 14 : 342–57. [CrossRef] [PubMed] [Google Scholar]
  22. Pike JW, Meyer MB, Lee S-M, et al. The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. J Clin Invest 2017 ; 127 : 1146–54. [CrossRef] [PubMed] [Google Scholar]
  23. Belorusova AY, Rochel N. Structural Studies of Vitamin D Nuclear Receptor Ligand-Binding Properties. Vitam Horm 2016 : 83–116. [PubMed] [Google Scholar]
  24. Abu el Maaty MA, Grelet E, Keime C, et al. Single-cell analyses unravel cell type-specific responses to a vitamin D analog in prostatic precancerous lesions. Sci Adv 2021 ; 7 : eabg5982. [CrossRef] [PubMed] [Google Scholar]
  25. Belorusova AY, Rochel N. Structural Studies of Vitamin D Nuclear Receptor Ligand-Binding Properties. Vitam Horm 2016 : 83–116. [CrossRef] [PubMed] [Google Scholar]
  26. Banach-Petrosky W, Ouyang X, Gao H, et al. Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice. Clin Cancer Res 2006 ; 12 : 5895–901. [CrossRef] [PubMed] [Google Scholar]
  27. Shahvazi S, Soltani S, Ahmadi S, et al. The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. Horm Metab Res 2019 ; 51 : 11–21. [CrossRef] [PubMed] [Google Scholar]
  28. Beer T. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Sem Oncol 2001 ; 28 : 49–55. [CrossRef] [Google Scholar]
  29. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res 2006 ; 26 : 2647–51. [PubMed] [Google Scholar]
  30. Abu el Maaty M, Wölfl S. Effects of 1,25(OH)2D3 on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents. Nutrients 2017 ; 9 : 87. [CrossRef] [PubMed] [Google Scholar]
  31. Beer TM. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005 ; 96 : 508–13. [CrossRef] [PubMed] [Google Scholar]
  32. Medioni J, Deplanque G, Ferrero J, et al. Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts). JCO 2011 ; 29 : 142. [CrossRef] [PubMed] [Google Scholar]
  33. Attia YM, El-Kersh DM, Ammar RA, et al. Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact 2020 ; 315 : 108865. [CrossRef] [PubMed] [Google Scholar]
  34. Huang Z, Zhang Y, Li H, et al. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3. Cell Death Dis 2019 ; 10 : 936. [CrossRef] [PubMed] [Google Scholar]
  35. Len-Tayon K, Beraud C, Fauveau C, et al. A vitamin D-based strategy overcomes chemoresistance in prostate cancer. Br J Pharmacol 2024 ; bph.16492. [Google Scholar]
  36. Chauchereau A, Al Nakouzi N, Gaudin C, et al. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 2011 ; 317 : 262–75. [CrossRef] [PubMed] [Google Scholar]
  37. Al Nakouzi N, Cotteret S, Commo F, et al. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget 2014 ; 5 : 667–78. [CrossRef] [PubMed] [Google Scholar]
  38. Galus Ł, Michalak M, Lorenz M, et al. Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy. Cancer 2023 ; 129 : 2047–55. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.